The effect of recombinant swine interleukin-4 on swine immune cells and on pro-inflammatory cytokine productions in pigs.
The in vitro effect and the in vivo influence of recombinant swine IL-4 (rSwIL-4) were characterized in various swine cells and in nursery pigs on LPS-induced endotoxic shock and pro-inflammatory cytokine productions. In in vitro experiment, the rSwIL-4 induced a proliferation of CD4 positive T cells in mitogen-prestimulated peripheral blood mononuclear cell (PBMC). In addition, the rSwIL-4, which was produced from insect cells, promoted the differentiation of monocytes into immature dendritic cells in combination with granulocyte macrophage-colony stimulating factor (GM-CSF). Furthermore, the rSwIL-4 successfully suppressed the LPS-induced secretion of TNF-alpha, IL-1alpha, IL-6, IL-8, and IL-18 from swine alveolar macrophages when rSwIL-4 was treated at the same time with LPS. In in vivo experiment in nursery pigs, subcutaneous pretreatment of rSwIL-4, which was produced from baculovirus expression system, enhanced the severity of respiratory failure with endotoxic shock, and increased the production of TNF-alpha and IL-18 in response to inoculation with LPS. These results indicate that the rSwIL-4 is biologically active in both in vitro and in vivo treatments. Depending on the administration time, pro-inflammatory cytokine productions by IL-4 can cause either inhibitory or stimulatory regulation.
Nuntaprasert
A
A
Laboratory of Animal Research Center, Institution of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai Minato-ku, Bunkyo-ku, Tokyo 108-8639, Japan.
Mori
Y
Y
Muneta
Y
Y
Yoshihara
K
K
Tsukiyama-Kohara
K
K
Kai
C
C
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D019556:COS Cells; D002522:Chlorocebus aethiops; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D005434:Flow Cytometry / Q000662:veterinary; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology; D020382:Interleukin-18 / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000276:immunology / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000276:immunology; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D012772:Shock, Septic / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D013047:Specific Pathogen-Free Organisms; D013552:Swine / Q000276:immunology*; D013553:Swine Diseases / Q000188:drug therapy / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D020382:Interleukin-18; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor